Biotech Firms Begin Developing Measles Treatments Amid Rising US Cases

Rising Measles Cases Drive New Treatment Development

Measles cases in the US have reached a 35-year high, with over 2,289 cases reported by July, surpassing the total for the previous year. This increase is attributed to declining vaccination rates, which have fallen below the 95% community immunity threshold needed to protect vulnerable populations.

In response to this resurgence, biotech companies and academic institutions have begun efforts to develop new treatments for measles. These treatments aim to provide options for infected individuals and short-term protection for those who cannot be vaccinated, such as infants under 12 months old and immunocompromised individuals.

Current Treatment Limitations

Historically, the high effectiveness of measles vaccination reduced the incentive for developing specific treatments. Consequently, current medical interventions for measles are limited to supportive care. Doctors focus on managing symptoms like dehydration and breathing difficulties, and administering steroids for inflammation. Vitamin A supplements are sometimes given to address depletion caused by the virus, but they do not directly target the virus itself.

Challenges and Outlook

The development of new measles countermeasures is expected to take several years before they become available. There is also uncertainty regarding the acceptance of such treatments by individuals who decline vaccinations. Michael Mina, an epidemiologist and chief medical officer of Invivyd, highlighted the current lack of options for exposed individuals, underscoring the urgent need for new therapeutic approaches.